What Got Me Thinking About This

I was watching Dodgers highlights with my son when Ketel Marte stepped in and hit one out. My kid thought it was great. I sat there quietly for a second, because I traded him. His injury history made me nervous, I acted on it, and he proceeded to have one of the best seasons by a second baseman in recent memory. That’ll do it.

More than the trade itself, what stuck with me was the question underneath it: does injury history actually predict future problems, or are we just pattern-matching on noise? Because if some injuries are genuinely predictive and others are one-time events with clean recovery paths, that’s something worth knowing — and most fantasy managers never make the distinction.

So I went and looked into it. There’s real research here — MLB epidemiological data, sports medicine literature, return-to-play studies. Combined with a few recent case studies that illustrate each scenario, here’s what I found. Happy to share it.

Injury history is only meaningful if you know what type of injury it was. Treating all IL stints equally is the mistake. The type, grade, and body part tell you almost everything.

Part I: The Marte Baseline

What His Injury History Actually Says

Marte has been on the IL every season from 2021 through 2025. That’s the fact that gets weaponized in trade conversations. But reading the record carefully tells a different story:

• 2021: Right hamstring strain — two IL stints, came back and played well
• 2022: Managed hamstring issues all year without the IL, but production suffered: .240 average, career-low BABIP, elevated strikeout rate — the classic “playing hurt” signature
• 2023: Healthy full season. Career resurgence. Played 139 games, .276/.349/.475, 25 HRs
• 2024: Ankle sprain (high ankle), August — initially reaggravated multiple times before the team finally shut him down. Came back for September. Still hit 36 HRs on the season
• 2025: Left hamstring, Grade 1, April. Missed roughly three weeks. Returned and led all 2B in wRC+ again

One soft-tissue IL stint per year. Averaging 137 games played over the last four seasons. That’s not an injury-prone player. That’s a player being intelligently managed by a franchise that knows his value.

The Diamondbacks’ use of the DH spot to protect Marte’s hamstring wasn’t a red flag — it was load management. The difference between “injury-prone” and “injury-managed” is one of the most actionable distinctions in fantasy baseball, and most managers never make it.

 

Teams that proactively use the IL and DH to protect assets are telling you something. They believe in the long-term value. Follow their lead, not your panic.

 

Part II: Not All Injuries Are Created Equal

The Grading System That Actually Matters

Every muscle strain in baseball receives a medical grade. This is the single most underused data point in fantasy baseball. Most managers hear “hamstring” and react. The grade tells you whether to panic, hold, or actually buy.

Grade 1 — Green Flag: Microtearing only, minimal function loss. Average time missed: under two weeks. Recurrence rate is real but manageable. When a team says “a few weeks” and the player was walking normally off the field, this is where you buy, not sell.

Grade 2 — Yellow to Red Flag: The most dangerous category for fantasy decision-making. Accounts for over 85% of IL-landing hamstring injuries. The severity range is enormous — anything from 5% fiber damage to just-short-of-complete tears. When teams say “multiple weeks,” they’re probably not being vague; they genuinely don’t know. This is where you hold in dynasty and get cautious in redraft.

Grade 3 — Red Flag: Complete tear. Surgery required. Season-ending. The only real question in redraft is how fast you can get something back in trade. In dynasty, stash and wait.

 

The Injury Types That Repeat vs. The Ones That Don’t

Hamstrings and obliques are the two injuries with the highest recurrence rates in professional baseball. Hamstrings in MLB re-occur at a 16.3% rate, and each subsequent injury results in more time missed than the last. Obliques are similar — up to 20% recurrence if the player returns before full trunk rotation is restored.

Contact injuries — broken fingers from HBP, ankle sprains from collisions, hamate fractures — are categorically different. They have clear timelines, low recurrence, and no predictive power for future injuries. A player who breaks a finger in June is not “injury-prone.” He got hit by a pitch. Buy the dip.

The injury that most consistently derails fantasy seasons without warning? Forearm tightness and elbow inflammation in pitchers. These sound minor. They’re not. They’re the canary in the coal mine for UCL damage, and the market rarely prices the downstream risk correctly until it’s too late.

 

The Hold/Sell Test: Ask yourself: Is this the same body part as last time, or a new one? Did the Statcast data hold up before the injury? Is the team managing proactively or playing him through pain? Two yes answers = hold. Three = buy.

 

Part III: Players Like Marte — Recent Case Studies

Ronald Acuña Jr. — The Two-ACL Test

Hamstring Strain (Gr. 1)

Flag

No player in recent fantasy history has stress-tested the injury framework harder than Acuña. After tearing his right ACL in 2021, he came back in 2022 as a diminished version of himself — .266 average, 15 home runs, clearly still adjusting. Then in 2023, one full year removed from surgery, he posted the first 40/70 season in MLB history: 41 HRs, 73 steals, .337 average, NL MVP. Anyone who sold low on him in 2022 based on the ACL history paid for it.

Then he tore the other ACL in May 2024. The fantasy community had already been through this movie. The panic was massive anyway. His draft stock cratered heading into 2025. The market couldn’t separate ‘this player tears ACLs’ from ‘this player tears ACLs on different knees, which are different injuries,’ and only one of those framings is accurate.

The result in 2025: 95 games, 21 home runs, .290/.417/.518 slash, 74 runs. Not MVP-level — but the tools were clearly intact. His exit velocity and hard-hit rate in his brief 2024 sample before the injury were elite. ACL returns in young, explosive athletes have an 88% return-to-play rate with no skill erosion predicted. The knee comes back. The bat comes back.

The first year back from ACL surgery is almost always a discount year. The second year is where you see the real player. Acuña proved this in 2023. He’s set up to prove it again in 2026.

 

Spencer Strider — When The Red Flag Is Real

Strider is the necessary counter-example. He’s not like Marte or Acuña. He’s the case where the concern was legitimate, and understanding the injury science explains why.

In 2024, his season lasted nine innings before a bone fragment cut into the UCL he’d already had repaired via Tommy John surgery in 2019. He avoided a full second TJ by opting for an internal brace procedure — shorter recovery, but limited return data and meaningful velocity risk. Fantasy managers bid him up for 2025 anyway, drafting him as high as 25th overall. His in-season velocity came in two full miles per hour below his 2023 peak. He posted a 4.45 ERA and the market felt the burn.

Now opening 2026 on the IL again with an oblique strain. The pattern is the pattern. The difference between Strider and Marte isn’t bad luck — it’s the type of injury and which part of the player’s game it affects. Hamstrings are wheels. The UCL is the engine. You can replace wheels. You cannot easily restore a pitcher’s velocity after elbow surgery. Once velocity drops, the margin for error on every other aspect of the game shrinks.

Strider isn’t broken. But the evidence you need to trust him again hasn’t appeared yet. In spring training, his four-seamer sat 93 mph — down nearly four ticks from his 2023 peak. That’s the only number that matters right now.

 

Cody Bellinger — The Case Where Underlying Data Told You The Truth

Bellinger’s 2023 Cubs season was one of the best buy-low stories in recent fantasy history. Coming off two years of post-ACL struggle in Los Angeles and a non-tender, he landed in Chicago and hit .307 with 26 home runs and 20 steals. Anyone who trusted his pre-injury track record got paid.

The tell that it wasn’t fully real? His average exit velocity of 87.9 mph was a career-worst, ranking in the bottom quartile of the league. The counting stats looked like a healthy Bellinger. The Statcast profile looked like a player performing above his current physical ceiling. He stepped back in 2024 before a HBP finger fracture ended things early. The Yankees chapter in 2025 showed the real baseline: 29 home runs, .272, solid but not elite.

Exit velocity is your truth serum. If a player comes back from injury and his counting stats recover but his exit velo doesn’t, that’s a performance built on BABIP luck and park factors. Marte’s exit velocity held. Bellinger’s didn’t. That’s the difference.

 

Rhys Hoskins — The Right Framework Applied to the Wrong Player

Hoskins missed all of 2023 after tearing his ACL in spring training. The 2024 setup looked textbook Marte-style buy-low: known talent, one-time structural injury, clean recovery pathway, new venue (Milwaukee) that plays well for right-handed power. He was being drafted well below his historical production level. ACL in a position player is recoverable. The prognosis was solid.

He came back and hit 26 home runs in 131 games. But his slash line was .214/.303/.419 and his exit velocity dropped further than pre-injury. Then a hamstring injury cost him two more months. By the time he returned, he’d lost his roster spot.

The framework wasn’t wrong. The variable that changed the calculus was age. Hoskins returned at 30. Acuña returned at 25. Age is a multiplier on every injury prognosis — physical tools degrade more slowly in younger athletes, and the body’s ability to fully compensate for structural repair diminishes with each year. A player under 28 returning from ACL surgery is a different asset than a player over 30 doing the same thing. Price them accordingly.

 

Byron Buxton — The Clearest Example of Injury-Managed vs. Injury-Prone

If Marte is the case that makes you question your sell instincts, Buxton is the one that proves the framework works — if you let it. His injury history is genuinely alarming on paper. He has played more than 92 games in a season just twice since 2017. The list of body parts that have landed him on the IL reads like a trauma inventory: knee, hip, hamstring, rib, back, calf, forearm, head. Fantasy managers have been burned enough times that his ADP craters every spring regardless of the actual prognosis.

But here’s what that record actually reflects: Buxton plays a high-impact style in center field — elite speed, aggressive routes, wall-crashing defense — on a body that the Twins have actively had to protect from itself. The knee surgeries in 2022 and 2023 were the structural anchor of all of it. Once those were resolved, the pattern changed.

In 2024, the Twins cleared him to play center field again after a full arthroscopic cleanup. He played 102 games, posted an .859 OPS, and hit the 86th percentile in hard-hit rate. In 2025, for the first time in nearly a decade, he entered a season with no offseason surgery and no rehab program. The result: 126 games, 35 home runs, 24 steals, 97 runs, 83 RBI, Silver Slugger, MVP votes. The Twins were so confident in his health they let him steal third base freely in spring training — something they’d restricted for years to limit exposure.

The Buxton lesson is the Marte lesson taken further. When a team’s injury management is load-bearing — when they’re actively designing how a player is deployed around his physical profile — the IL stints are part of the plan, not signs of breakdown. The Twins weren’t surprised by Buxton’s injuries. They were managing around a player whose tools, when healthy, sit in the top handful in the sport. The market kept pricing the history. The Twins kept protecting the asset.

His 2026 ADP jumped from 210 to 59. The market finally caught up. That’s what happens when you read the injury type correctly and hold — someone else pays the full price later.

 

Buxton vs. Marte: Two players with long IL histories. Both managed proactively by their teams. Both with elite underlying tools that held through the injuries. The difference is volume — Buxton’s knee required two surgeries before the root issue was fully resolved. Once it was, the player the Twins always believed in showed up. Give structural injuries time to resolve before writing off the talent.

Part IV: The Decision Framework

Hold, Buy, or Move On — Five Questions to Run

Before reacting to an injury update, work through these in order:

• 1. What TYPE of injury is it? Soft tissue (hamstring, oblique, calf) carries recurrence risk. Structural one-time events (broken bones, sprains from collisions, HBP fractures) don’t. Elbow issues in pitchers are always elevated concern.
• 2. What GRADE is it? Grade 1 = buy window. Grade 2 = hold and monitor. Grade 3 = cut in redraft, stash in dynasty.
• 3. Is it the SAME BODY PART as a prior injury? Same site recurrence elevates risk meaningfully, especially hamstrings and obliques. Different body part = don’t conflate the histories.
• 4. What does STATCAST say? Check exit velocity, hard-hit rate, and sprint speed in the weeks before the injury. If those numbers were elite, the tools are intact. If they were declining pre-injury, the player was already compromised.
• 5. How is the TEAM handling it? Proactive IL usage, DH splits, and extended rehab timelines are green flags. Teams playing stars through obvious symptoms are the real warning sign.

 

The Bottom Line: The players who wreck fantasy rosters aren’t the ones who get hurt. They’re the ones sold cheaply because they got hurt, right before the market reprices them back to elite. Don’t be the seller.

 

Part V: Injury Reference Tables

Hitter Injury Classification
Sources: MLB Health and Injury Tracking System (2011–2021); Orthopaedic Journal of Sports Medicine; PMC epidemiological studies; FantraxHQ, RotoWire, ESPN injury primers.

Injury Type Avg. Days Missed Recurrence Profile Fantasy Action Flag
Hamstring Strain (Gr. 1) 10–16 days ~16% recurrence in MLB; higher if same limb Monitor sprint speed on return. Buy-low window if Statcast intact. 🟡 YELLOW
Hamstring Strain (Gr. 2) 21–35 days Highest recurrence risk of all grades; Grade II = 24% re-injury Hold in dynasty. Sell in redraft if ADP still inflated. 🔴 RED
Hamstring Strain (Gr. 3) Season-ending Surgery required; multi-month return Cut in redraft. Stash in dynasty only. 🔴 RED
Oblique Strain 22–45 days 12–20% recurrence; higher if return is rushed Treat like a hamstring. Rotational power at risk until fully healed. 🔴 RED
Ankle Sprain (Low) 7–18 days Low recurrence if fully healed; high ankle = more risk Depends on grade. High ankle = extended caution. 🟡 YELLOW
Ankle Sprain (High) 21–45 days Reaggravation common if returned early (see Marte 2024) Don’t rush. Watch for repeat IL stints. 🔴 RED
ACL Tear 9–12 months 88% return rate; 2nd ACL possible but not predictive of 3rd Stash if young (Acuña model). Discount older veterans. 🟡 YELLOW
Broken Finger/Hand (HBP) 3–6 weeks Low — traumatic, one-time event Buy-low. Unrelated to player durability. 🟢 GREEN
Hamate Fracture 4–8 weeks Low recurrence; power dip common on return (2–4 weeks) Watch exit velocity on return. Typically safe to hold. 🟢 GREEN
Wrist Tendinitis Variable Moderate; can become chronic in contact-heavy players Chronic pattern = sell. First occurrence = hold. 🟡 YELLOW
Knee Contusion / Meniscus 2–6 wks (contusion); 4–8 wks (meniscus) Meniscus: moderate recurrence without surgery Contusion = buy dip. Meniscus tear = investigate surgery status. 🟡 YELLOW
Back / Lumbar Strain 14–30 days Elevated recurrence; chronic back issues are career-long Multiple back stints = structural concern. Sell. 🔴 RED
Pitcher Injury Classification
Sources: MLB Health and Injury Tracking System; OJSM UCL and soft tissue studies; RotoWire, CBS Sports, and FantasyPros pitcher return-to-play analysis (2024–2026).

Injury Type Avg. Days Missed Recurrence Profile Fantasy Action Flag
Tommy John (UCL Tear) 12–18 months ~25–30% require 2nd TJ; velocity often down Yr 1 back Stash in dynasty. Avoid in redraft Yr 1 back unless late rounds. 🔴 RED
UCL Internal Brace 10–14 months Shorter recovery than TJ but limited long-term data; velocity loss common Cautious hold. Velocity in spring training is your key indicator. 🟡 YELLOW
Elbow Inflammation 2–6 weeks High recurrence; often precursor to structural damage Chronic pattern = sell before the market catches on. 🔴 RED
Oblique Strain 22–45 days 12–20% recurrence; rotation is everything for pitchers More dangerous for pitchers than hitters. Longer recovery floor. 🔴 RED
Shoulder Inflammation 2–6 weeks Moderate to high; can mask rotator cuff damage Demand MRI clarity. Vague “inflammation” = elevated concern. 🟡 YELLOW
Rotator Cuff Strain 4–12 weeks High recurrence; elite velocity at risk long-term Age matters. Under 28 = hold. Over 30 = sell. 🔴 RED
Forearm Tightness / Flexor Strain 2–6 weeks Strong predictor of UCL damage downstream; watch closely Buy if first occurrence + negative MRI. Sell if it recurs. 🟡 YELLOW

Sources: MLB Health and Injury Tracking System; OJSM UCL and soft tissue studies; RotoWire, CBS Sports, and FantasyPros pitcher return-to-play analysis (2024–2026).

Closing Thought

The best fantasy managers aren’t the ones who avoid injured players. They’re the ones who know which injuries to fear and which ones to buy through. That distinction, applied consistently across a season, is where leagues are won.